GET DAILY SIGNALSWhy Is Travere Therapeutics (TVTX) Stock Down -6.82% Today?
Key Takeaways
- Shares of Travere Therapeutics fell roughly 6.82% to about $45.90, down from a prior close of $49.26.
- The primary catalyst was a third-quarter earnings report that posted a wider-than-expected loss, driven largely by a one-time in-process R&D charge tied to its civorebrutinib licensing deal with Everest Medicines.
- Investors also reacted to softer new patient start forms for FILSPARI, which declined sequentially, clouding the near-term commercial ramp.
- Revenue topped estimates and FILSPARI net sales crossed $200 million, but the headline EPS miss and slowing patient demand overshadowed the revenue beat.
- The decline pushed the stock toward key technical support near its 200-day moving average, a closely watched level for traders.
- For deeper analysis of this ticker's valuation and expectations, explore Price Targets, Earnings, and Forecast pages.
- For AI-driven trading signals on this and thousands of other tickers, explore Trending AI Robots.
Opening Summary
Travere Therapeutics, Inc. (TVTX), a San Diego–based biopharmaceutical company focused on rare kidney and metabolic diseases, saw its shares slide sharply in Tuesday's session. The stock fell about 6.82%, trading near $45.90 after closing the prior session at $49.26. The selling pressure followed the company's third-quarter 2026 results, which delivered a headline earnings miss and signs of decelerating new-patient demand for its flagship therapy, FILSPARI (sparsentan) — even as revenue came in well above Wall Street's expectations.
Q3 Earnings Miss Weighs on Sentiment
The most immediate driver of the decline was the company's quarterly report. Travere posted a GAAP loss of $0.55 per share, versus a consensus estimate of a modest $0.02 profit. On a non-GAAP basis, the loss was $0.31 per share, also short of expectations. A substantial portion of that miss stemmed from a $113.1 million in-process research and development expense related to the company's exclusive licensing and collaboration agreement with Everest Medicines for civorebrutinib — a one-time item that converted what would otherwise have been an operating profit into an operating loss.
The revenue picture was notably stronger. Total revenue reached $224.56 million, beating the consensus estimate of roughly $195.68 million and reflecting growth of about 98% year over year. FILSPARI net product sales climbed to $200.2 million, a gain of 120% versus the prior-year quarter.
Softer New-Patient Starts Cloud the Ramp
Despite the revenue beat, the market focused on a more cautious signal: Travere received 1,932 new patient start forms for FILSPARI during the quarter, down sequentially from 2,012 in the prior quarter. Management attributed the dip in part to seasonality and prior-quarter pull-forward, while noting that IgA nephropathy (IgAN) patient starts, though still elevated, fell numerically. The company also flagged expected quarter-over-quarter variability in IgAN starts as competing therapies vie for physician attention. Investors interpreted the commentary as a sign that the commercial expansion of FILSPARI, while still healthy, may be moderating near term.
Market Context and Trading Activity
The decline was accompanied by elevated trading activity, with volume running above the stock's typical daily average as investors repriced the earnings and guidance. The move pushed shares below their 50-day moving average and toward the 200-day line near the mid-$46 range — a technical zone that has historically acted as support. The pullback also reflected broader sensitivity in the mid-cap biotech space, where high-growth, high-multiple names can see outsized reactions to any perceived slowdown in launch momentum, even when underlying fundamentals remain solid.
What Comes Next for TVTX
Looking ahead, investors will be watching several key variables for TVTX. Management reaffirmed full-year gross-to-net guidance and continues to enroll the Phase 3 HARMONY study of pegtibatinase for classical homocystinuria, with topline results expected in the second half of 2027. A planned leadership transition is also on the horizon, with CEO Eric Dube handing the reins to Bradley Campbell later this year, a change that adds a layer of execution uncertainty. Additionally, the company has cautioned that a specialty pharmacy inventory build that flattered third-quarter FILSPARI sales is expected to reverse in the fourth quarter. Risks include competitive pressure in the IgAN market, potential quarter-to-quarter volatility in patient starts, and ongoing operating expense growth tied to the FSGS launch.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's strongest-performing automated trading strategies. Tickeron offers hundreds of AI trading bots covering thousands of tickers, each differing by strategy, timeframe, performance metrics, and the symbols it trades. Only the bots performing best under current market conditions are featured in this section. Explore Trending AI Robots to see which strategies are currently outperforming.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
TVTX's Indicator enters downward trend
The Aroon Indicator for TVTX entered a downward trend on November 02, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 189 similar instances where the Aroon Indicator formed such a pattern. In 151 of the 189 cases the stock moved lower. This puts the odds of a downward move at 80%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TVTX as a result. In 80 of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
The 10-day moving average for TVTX crossed bearishly below the 50-day moving average on September 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TVTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where TVTX's RSI Oscillator exited the oversold zone, 24 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for TVTX just turned positive on October 22, 2026. Looking at past instances where TVTX's MACD turned positive, the stock continued to rise in 39 of 45 cases over the following month. The odds of a continued upward trend are 87%.
Following a +4.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where TVTX advanced for three days, in 217 of 283 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
TVTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 35 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 48 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. TVTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 100 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: TVTX's P/B Ratio (238.095) is very high in comparison to the industry average of (3.104). P/E Ratio (17.370) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (5.690) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (9.794) is also within normal values, averaging (439.647).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company, which develops pharmaceutical products
Industry Biotechnology
Advertisement